SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer headquartered in Sydney, Australia, on January 11, 2016. The filing serves to distribute an ASX Price Query Response (Exhibit 99.1) to U.S. investors. The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing referencing an external response to a price query and contains no embedded financial statements or performance data.
Material Changes
No material changes versus a prior comparable period are disclosed in this filing. The document does not contain comparative financial data or operational updates.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the cover page and exhibit index for the ASX Price Query Response.
Key Facts for Investor Verification
- Verify the content of the attached "ASX Price Query Response" (Exhibit 99.1) to understand the specific market inquiry addressed.
- Confirm the company's current trading status and share price on the Australian Securities Exchange (ASX).
- Review the most recent Form 20-F or interim reports for actual financial performance data, as this filing contains none.
- Note that the Chief Executive Officer, Marc Voigt, signed the filing on behalf of the registrant.